Work

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.9003

Authors: Ferdinandos Skoulidis, Bob T. Li, Ramaswamy Govindan, Grace K. Dy, Geoffrey Shapiro, Joshua Bauml, Martin H. Schuler, Alfredo Addeo, Terufumi Kato, Benjamin Besse, Abraham Anderson, Agnes Ang, Gataree Ngarmchamnanrith, Qui Tran, Vamsidhar Velcheti

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Roswell Park Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Pennsylvania, Essen University Hospital, University Hospital of Geneva, Kanagawa Cancer Center, Institut Gustave Roussy, Fondation Gustave Roussy, Amgen (United States), NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3167020670

Cites:

Cited by: 24

Related to: 10